

REMARKS

Claims 1-10, 13-16, 19-20, 22-23, and 25-28 are pending in the present application.

The Examiner has required election in the present application between:

Group I, claims 1-8, 13, 14, 19, 22 and 25-28, drawn to plasminogen derivatives;

Group II, claims 1-8, 13, 14, 19, 22 and 25-28, drawn to endostatin derivatives;

Group III, claims 1-8, 13, 14, 19, 22 and 25-28, drawn to VEGF derivatives; and

Group IV, claims 1-8, 13, 14, 19, 22 and 25-28, drawn to KDR/FLK-1 derivative.

For the purpose of examination of the present application, Applicants elect, with traverse, Group II, drawn to endostatin derivatives. Applicants traverse the requirement for restriction on the grounds that the inventions of Groups I-IV as disclosed and claimed in this application would most efficiently be examined together herein.

Since claims 9, 10, 15, 16, 20, and 23 were not restricted out or designated as being withdrawn from consideration by the

Examiner, it is presumed that claims 9, 10, 15, 16, 20, and 23 will be examined along with the invention of Group II.

Should there be any outstanding matters that need to be resolved in the present application, the Examiner is respectfully requested to contact Richard Gallagher (Reg. No. 28,781) at the telephone number of the undersigned below, to conduct an interview in an effort to expedite prosecution in connection with the present application.

If necessary, the Commissioner is hereby authorized in this, concurrent, and future replies, to charge payment or credit any overpayment to Deposit Account No. 02-2448 for any additional fees required under 37 C.F.R. § 1.16 or under 37 C.F.R. § 1.17; particularly, extension of time fees.

Respectfully submitted,

BIRCH, STEWART, KOLASCH & BIRCH, LLP

By Mark J. Nuell
Mark J. Nuell, #36,623


DRN/RG/csm
1781-0215P

P.O. Box 747
Falls Church, VA 22040-0747
(703) 205-8000